Anorexia-Cachexia Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034
Anorexia-Cachexia Syndrome (CS) Market Outlook
Thelansis’s “Anorexia-Cachexia
Syndrome (CS) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Anorexia-Cachexia Syndrome (CS) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Anorexia-Cachexia
Syndrome (CS) Overview
Cachexia
Syndrome (CS) is a multifactorial syndrome characterized by body weight loss,
declining muscle mass and function, wasting, and inflammation of adipose
tissues accompanied by metabolic dis-arrangement, anorexia, systemic
inflammation, and insulin resistance. The clinical relevance of cachexia is
shown by its impact on both the prognosis and the efficacy of treatment against
the underlying disease as well as survival time and quality of life. Cachexia
is typically associated with a number of underlying chronic degenerative
diseases, such as cancer, chronic obstructive pulmonary disease (COPD), HIV,
chronic heart failure, diabetes, liver failure, rheumatoid arthritis, and
chronic kidney failure. Chronic conditions share several underlying mechanisms and
ultimately have similar output, i.e., severe muscle wasting. However, the
multifactorial origin of cachexia and its multisystem involvement made the
study of this syndrome in the context of underlying chronic diseases. This is
also characterized by an ongoing loss of skeletal muscle that cannot be fully
reversed by conventional nutritional support and leads to progressive
functional impairment.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment